Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.46 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28849731 | 0.88 | SMN1; SMN2 (0.42) | ALDH1A1TSHRMAPK1SMN1; SMN2TDP1 | |
| SCHEMBL3370049 | 0.85 | — | — | |
| SCHEMBL4435149 | 0.85 | — | — | |
| SCHEMBL2725302 | 0.85 | — | — | |
| SCHEMBL6220568 | 0.81 | — | — | |
| SCHEMBL11297789 | 0.81 | — | — | |
| SCHEMBL10455967 | 0.81 | ALDH1A1 (0.40) | ALDH1A1TSHRMAPK1SMN1; SMN2TDP1 | |
| SCHEMBL28400161 | 0.81 | — | — | |
| SCHEMBL18241835 | 0.81 | — | — | |
| SCHEMBL29114779 | 0.81 | ALDH1A1 (0.36) | ALDH1A1TSHRMAPK1SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 549 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048005-A1 | INJECTABLE THERMOSENSITIVE HYDROGELS FOR A SUSTAINED RELEASE OF IRON NANOCHELATORS | MASSACHUSETTS GEN HOSPITAL (US) | 2026-02-19 | — | — | US | claimed |
| US-20260034269-A1 | IMPLANTS FOR SCULPTING, AUGMENTING OR CORRECTING FACIAL FEATURES SUCH AS THE CHIN | ALLERGAN IND SAS (FR) | 2026-02-05 | — | — | US | claimed |
| EP-4572752-A1 | INJECTABLE THERMOSENSITIVE HYDROGELS FOR A SUSTAINED RELEASE OF IRON NANOCHELATORS | The General Hospital Corporation (US) | 2025-06-25 | — | — | EP | claimed |
| US-20240307289-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN APPEARANCE | ALLERGAN IND SAS (FR) | 2024-09-19 | — | — | US | claimed |
| EP-4431531-A1 | METHOD FOR PREPARING COMPOSITION CONTAINING HYALURONIC ACID CROSSLINKED PRODUCT | Yoo Young Pharm Co., Ltd. (KR) | 2024-09-18 | — | — | EP | claimed |
| US-12011500-B2 | Compositions and methods for improving skin appearance | ALLERGAN INDUSTRIE, SAS (FR) | 2024-06-18 | — | — | US | claimed |
| EP-4346922-A2 | PACKAGING SOLUTIONS | Bausch + Lomb Ireland Limited (IE) | 2024-04-10 | — | — | EP | claimed |
| WO-2024039584-A1 | INJECTABLE THERMOSENSITIVE HYDROGELS FOR A SUSTAINED RELEASE OF IRON NANOCHELATORS | THE GENERAL HOSPITAL CORPORATION (US) | 2024-02-22 | — | — | WO | claimed |
| US-11857682-B2 | Hyaluronate compositions and soft tissue fillers | AMC GROUP LLC (US) | 2024-01-02 | — | — | US | claimed |
| US-11845813-B2 | Crosslinked polymeric network and use thereof | BAUSCH & LOMB INCORPORATED (US) | 2023-12-19 | — | — | US | claimed |
| US-20100028438-A1 | Hyaluronic Acid-Based Gels Including Lidocaine | ALLERGAN INDUSTRIE, SAS (FR) | 2010-02-04 | — | — | US | claimed |
| US-20100028437-A1 | Hyaluronic Acid-Based Gels Including Lidocaine | ALLERGAN INDUSTRIE, SAS (FR) | 2010-02-04 | — | — | US | claimed |
| US-20100004198-A1 | POLYSACCHARIDE GEL FORMULATION HAVING INCREASED LONGEVITY | ALLERGAN, INC. (US) | 2010-01-07 | — | — | US | claimed |
| US-20090143331-A1 | POLYSACCHARIDE GEL FORMULATION HAVING INCREASED LONGEVITY | ALLERGAN INDUSTRIE, SAS (FR) | 2009-06-04 | — | — | US | claimed |
| JP-2006522851-A | — | — | 2006-10-05 | — | — | JP | claimed |
| EP-1611160-A2 | CROSS-LINKING OF LOW AND HIGH MOLECULAR WEIGHT POLYSACCHARIDES PREPARATION OF INJECTABLE MONOPHASE HYDROGELS AND POLYSACCHARIDES AND HYDROGELS THUS OBTAINED | CORNEAL INDUSTRIE (FR) | 2006-01-04 | — | — | EP | claimed |
| EP-1303542-B1 | PREPARATION OF CROSSLINKED HYALURONIC ACID AND THE HYDROGEL THEREFROM, THE PRODUCTS OBTAINED AND THE USES THEREOF | D ESTHETIQUE APPLIQUEE LAB (FR) | 2005-08-31 | — | — | EP | claimed |
| US-6921819-B2 | Polysaccharide crosslinking, hydrogel preparation, resulting polysaccharide(s) and hydrogel(s), uses thereof | LABORATOIRES D'ESTHETIQUE APPLIQUEE (FR) | 2005-07-26 | — | — | US | claimed |
| WO-2004092222-A2 | CROSS-LINKING OF LOW AND HIGH MOLECULAR WEIGHT POLYSACCHARIDES PREPARATION OF INJECTABLE MONOPHASE HYDROGELS AND POLYSACCHARIDES AND HYDROGELS THUS OBTAINED | CORNEAL INDUSTRIE (FR) | 2004-10-28 | — | — | WO | claimed |
| US-20030148995-A1 | Polysaccharide crosslinking, hydrogel preparation, resulting polysaccharide(s) and hydrogel(s), uses thereof | CORNEAL INDUSTRIE, SAS (FR) | 2003-08-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048005-A1 | INJECTABLE THERMOSENSITIVE HYDROGELS FOR A SUSTAINED RELEASE OF IRON NANOCHELATORS | CD44, FECH, HSF1 | ALDH1A1 300/4885TSHR 563/4885MAPK1 4146/4885 |
| US-11845813-B2 | Crosslinked polymeric network and use thereof | CD44, GLMN, ALG1 | ALDH1A1 725/4885TSHR 2945/4885MAPK1 1487/4885 |
| US-20260034269-A1 | IMPLANTS FOR SCULPTING, AUGMENTING OR CORRECTING FACIAL FEATURES SUCH AS THE CHIN | HBB, COL1A1, COL2A1 | ALDH1A1 3552/4885TSHR 3516/4885MAPK1 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.